XML 53 R22.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Stockholders' Equity and Stock-Based Compensation Plans | 3 Months Ended
--- | ---
Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] |
Stockholders' Equity and Stock-Based Compensation Plans | NOTE 13 – STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION PLANS At March 31, 2014, the Company had authorized common stock of 40,000,000 shares (December 31, 2013 – 40,000,000). Issued shares at March 31, 2014, were 29,554,500 (December 31, 2013 – 29,554,500) and treasury stock amounted to 5,168,037 shares (December 31, 2013 – 5,207,947). The Company grants stock options and stock equivalent units (“SEUs”) from time to time as a long-term performance incentive. In certain cases the grants are subject to performance conditions such as the Company’s stock price. Where performance conditions apply the Monte Carlo simulation model is used to determine the fair values. Otherwise the Black-Scholes model is used to determine the fair values. Stock option plans The Company has four active stock option plans, two of which provide for the grant of stock options to employees and one provides for the grant of stock options to non-employee directors. The fourth plan is a savings plan which provides for the grant of stock options to all Company employees provided they commit to make regular savings over a pre-defined period which can then be used to purchase common stock upon vesting of the options. The stock options have discrete vesting periods which range from 24 months to 6 years and in all cases stock options granted expire within 10 years of the date of grant. All grants are at the sole discretion of the Compensation Committee of the Board of Directors. Grants may be priced at market value or at a premium or discount (including at no cost). The aggregate number of shares of common stock reserved for issuance which can be granted under the plans is 2,640,000. The following table summarizes the transactions of the Company’s stock option plans for the three months ended March 31, 2014:
|  | Number of Options |  |  | Weighted Average Exercise Price |  |  | Weighted Average Grant-Date Fair Value |
Outstanding at December 31, 2013 |  |  | 447,390 |  |  | $ | 7.33 |  |  |  |  |
Granted—at discount |  |  | 55,176 |  |  | $ | 0.00 |  |  | $ | 33.44 |
—at market value |  |  | 21,542 |  |  | $ | 46.03 |  |  | $ | 14.18 |
Exercised |  |  | (43,770 | ) |  | $ | 6.16 |  |  |  |  |
Forfeited |  |  | (2,844 | ) |  | $ | 10.36 |  |  |  |  |
Outstanding at March 31, 2014 |  |  | 477,494 |  |  | $ | 8.32 |  |  |  |  |
At March 31, 2014, there were 158,829 stock options that were exercisable, of which 67,001 had performance conditions attached. The Company’s policy is to issue shares from treasury stock to holders of stock options who exercise those options, but if sufficient treasury stock is not available, the Company will issue previously unissued shares of stock to holders of stock options who exercise options. The total compensation cost for the first three months of 2014 was $0.6 million (2013 – $0.7 million). The total intrinsic value of options exercised in the first three months of 2014 was $0.5 million (2013 – $1.9 million). The total compensation cost related to non-vested stock options not yet recognized at March 31, 2014 was $3.8 million and this cost is expected to be recognized over the weighted-average period of 2.31years. Stock equivalent units SEUs have discrete vesting periods which range from 11 months to 4 years and in all cases SEUs granted expire within 10 years of the date of grant. Grants may be priced at market value or at a premium or discount (including at no cost). There is no limit to the number of SEUs that can be granted. The liability for SEUs is located in accrued liabilities in the consolidated balance sheets until they are cash settled. The following table summarizes the transactions of the Company’s SEUs for the three months ended March 31, 2014:
|  | Number of SEUs |  |  | Weighted Average Exercise Price |  |  | Weighted Average Grant-Date Fair Value |
Outstanding at December 31, 2013 |  |  | 403,262 |  |  | $ | 3.64 |  |  |  |  |
Granted—at discount |  |  | 48,213 |  |  | $ | 0.00 |  |  | $ | 33.04 |
—at market value |  |  | 7,147 |  |  | $ | 46.03 |  |  | $ | 14.18 |
Exercised |  |  | (141,600 | ) |  | $ | 5.52 |  |  |  |  |
Forfeited |  |  | (3,847 | ) |  | $ | 9.60 |  |  |  |  |
Outstanding at March 31, 2014 |  |  | 313,175 |  |  | $ | 3.21 |  |  |  |  |
At March 31, 2014 there were 100,593 SEUs that are exercisable, of which 88,645 had performance conditions attached. The charges for SEUs are spread over the life of the award subject to a revaluation to fair value each quarter. The revaluation may result in a charge or a credit to the income statement in the quarter dependent upon our share price and other performance criteria. The total compensation cost for the first three months of 2014 was $0.6 million (2013—$3.7 million). The total intrinsic value of SEUs exercised in the first three months of 2014 was $3.0 million (2013 – $1.2 million). The weighted-average remaining vesting period of non-vested SEUs is 1.72 years. Long-term incentive plan In the first quarter of 2014, Innospec granted a long-term incentive plan to reward selected executives with a bonus for delivering exceptional performance. One of the elements of the plan is payable if the Innospec share performance matches or out-performs that of competitors, as measured by the Russell 2000 Index, over the performance period January 1, 2014 to December 31, 2016. The maximum bonus payable under this element of the plan is $3 million. Under GAAP this element is determined to be share-based compensation and as such the fair value of these liability cash-settled stock appreciation rights is calculated on a quarterly basis. The fair value is calculated using a Monte Carlo model and is summarized as follows:
(in millions) |  | 2014 |
Balance at January 1 |  | $ | 0.0 |
Compensation charge for the period |  |  | 0.1 |
Balance at March 31 |  | $ | 0.1 |
The following assumptions were used in the Monte Carlo model at March 31, 2014:
|  | 2014 |
Dividend yield |  |  | 1.11 | %
Volatility of Innospec’s share price |  |  | 36.0 | %
Risk free interest rate |  |  | 0.90 | %

X
- Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for accounts comprising shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income, and compensation-related costs for equity-based compensation. Includes, but is not limited to, disclosure of policies, compensation plan details, equity-based arrangements to obtain goods and services, deferred compensation arrangements, and employee stock purchase plan details. + References No definition available. + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration